BioAffinity Technologies (BIAF) Stock Jumps 55% on CyPath Lung Cancer Survivor Monitoring News
BioAffinity Technologies (BIAF) stock rallied 55% after revealing CyPath Lung's potential to monitor lung cancer survivors for recurrence. Volume hit 17M shares.
The post BioAffinity Technologies (BIAF) Stock Jumps 55% on CyPath Lung Cancer Survivor Monitoring News appeared first on Blockonomi.
Source: Source: Blockonomi